Nevada Med Spa Regulation in 2026: A Registry Is Coming to the 2027 Session, and the Complaints Behind It

Nevada has one of the highest densities of med spas per resident in the country, and until now almost no med spa-specific law. The term "med spa" is not defined in state statute. That is the gap regulators are preparing to fill, and for clinic owners the useful question is what the proposal would require and how much of it you can do now.

The Draft Med Spa Registry

The Nevada State Board of Medical Examiners has drafted a package of statute changes for the 2027 session that would enact the American Society for Dermatologic Surgery's model med spa safety act. As the draft reads, it would do the following.

• Public registry: an online list of each med spa's name and address, plus its medical director's name, license number and whether the director is an MD or DO.
• Fee and scope: a $500 annual fee, with registration covering any physician office offering cosmetic services.
• Existing spas: pre-existing spas would have to register within 90 days, and the drafting note proposes an effective date of January 1, 2028.
• PA changes: the same package floats a "physician associate" designation for PAs with 4,000 hours of experience who collaborate with a physician.

Why It Is Moving: The March 2026 Hearing

At an interim legislative committee hearing on March 31, 2026, the Board of Pharmacy's executive secretary, speaking for several boards, said med spa complaints are now that board's largest category and were near zero four years ago. He pointed to unlicensed operators, counterfeit drugs, physician licenses lent to others and salon models built on contractors. The state health authority said it has no authority over med spas and would need legislation and staff. Legislators were split between creating new standards and enforcing existing law, but the direction of travel is clear. The Medical Board's legislative subcommittee discussed the medical spa proposal in August 2026, and we could not find the outcome, so check its minutes.

Compounded GLP-1s: The Pharmacy Board's Notice

In a June 2, 2025 notice, the Nevada Board of Pharmacy told pharmacies that 503A pharmacies may no longer compound, distribute or dispense compounded tirzepatide or semaglutide, and that outsourcing facilities were cut off for semaglutide after May 22, 2025. It also reminded 503A pharmacies that they cannot sell compounded drugs to practitioners for office use. Violations can bring a citation or fine under state pharmacy law. A separate proposal to overhaul Nevada's compounding rules, including registration for practitioners who compound or mix in the office, was discussed in 2025, but we could not confirm a hearing or adoption.

What Was Enacted in 2025

• AB 319: effective January 1, 2026. It lets medical assistants work under RN supervision, applies tumescent anesthesia rules to PAs and anesthesiologist assistants (with a grace period for existing sites to July 1, 2026), adds a licensee email requirement and a screening requirement for patients aged 12 to 18. It affects aesthetic and liposuction-adjacent practices.
• Nursing Board decisions: in early 2025 the Board approved scope-of-practice limits for RNs and LPNs performing cosmetic procedures and moved to add LPNs to the out-of-hospital IV hydration decision. In May 2026 it began revising its aesthetic procedures decision. The finalization of these items is unconfirmed.
• Failed: SB 294, which would have removed PA supervision in favor of collaboration, passed the Senate and died in the Assembly. Existing supervision rules remain.

Ownership and Control

We found no Nevada corporate practice of medicine change in 2025 or 2026. A 2023 bill on the subject was vetoed. In our classification Nevada is a moderate CPOM state, meaning ownership structure matters even though it is less strictly enforced than in Texas or California. The registry proposal, if enacted, would make the medical director's name public, which raises the stakes on whether that physician really holds clinical authority.

Federal Items

FDA's February 2026 statement on compounded GLP-1 marketing, its warning letters to telehealth companies and its proposal to exclude semaglutide, tirzepatide and liraglutide from the 503B bulks list (not final when we checked) apply in Nevada. DEA telemedicine flexibilities for controlled substances, including testosterone, run through December 31, 2026. A federal bill introduced in September 2026 would restrict MSO control of practices nationally, but it is not expected to pass soon.

How a Nevada Med Spa Can Get Ready

• Make sure your medical director is a real, engaged physician. A public registry will list them by name.
• Document who your delegating physician is, what protocols exist for each service and how chart review happens.
• Stop sourcing compounded tirzepatide or semaglutide from Nevada 503A pharmacies, and do not buy compounded office stock from 503A pharmacies.
• Check that every RN, LPN, MA and aesthetician is working within the current Nursing Board decisions and AB 319.
• Keep drug sourcing, storage and adverse event records in order. Complaints about counterfeit drugs and lent licenses are what drove the proposal.
• Watch the Medical Board's agendas and the 2027 session's bill list.

Where MedGrid Fits

MedGrid connects Nevada clinics with a Nevada-licensed physician who holds real clinical authority, builds protocols and standing orders for each service, and sets up the physician-owned entity and management company structure so your documentation already looks like what a registry would ask for. That is a description of how we work, not a prediction of what the Legislature will pass.

Frequently Asked Questions

• Is there a Nevada med spa license?: Not yet. The Medical Board is drafting a registry proposal for the 2027 session, which is not law.
• When would the registry start?: The draft package suggests January 1, 2028 if enacted, with existing spas registering within 90 days.
• Can Nevada pharmacies compound tirzepatide or semaglutide?: Per the Board of Pharmacy's June 2025 notice, 503A pharmacies may not compound, distribute or dispense them, and cannot supply compounded drugs to practitioners as office stock.
• Did Nevada pass PA independence?: No. SB 294 died in the Assembly, and existing supervision rules remain.
• Does Nevada enforce corporate practice of medicine?: It is a moderate CPOM state in our classification. We found no change in 2025 or 2026.

This article is general educational information, not legal advice. The registry is a draft that may change or not be enacted, and several statuses could not be confirmed against final primary text. Consult licensed Nevada healthcare counsel.